A Study of TAK-861 for the Treatment of Narcolepsy Type 1

PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

June 3, 2025

Study Completion Date

June 3, 2025

Conditions
Narcolepsy Type 1
Interventions
DRUG

TAK-861

Oral tablet.

DRUG

Placebo

TAK-861-matching placebo tablet.

Trial Locations (53)

450

Takeda Site 33, Oslo

1004

Takeda Site 37, Vitoria-Gasteiz

3010

Takeda Site 23, Bern

5017

Takeda Site 22, Barmelweid

5021

Takeda Site 27, Bergen

8035

Takeda Site 35, Barcelona

10117

Takeda Site 34, Berlin

12004

Takeda Site 38, Castellon

17821

Takeda Site 49, Danville

19053

Takeda Site 26, Schwerin

23510

Takeda Site 10, Norfolk

28037

Takeda Site 2, Denver

28046

Takeda Site 24, Madrid

29201

Takeda Site 1, Columbia

30328

Takeda Site 3, Atlanta

31059

Takeda Site 43, Toulouse

32803

Takeda Site 4, Orlando

34090

Takeda Site 25, Montpellier

40139

Takeda Site 30, Bologna

44195

Takeda Site 42, Cleveland

45227

Takeda Site 6, Cincinnati

46600

Takeda Site 41, Valencia

63123

Takeda Site 5, St Louis

69004

Takeda Site 40, Lyon

75013

Takeda Site 29, Paris

75231

Takeda Site 44, Dallas

85054

Takeda Site 48, Phoenix

91786

Takeda Site 18, Upland

92705

Takeda Site 31, Santa Ana

93053

Takeda Site 47, Regensberg

94063

Takeda Site 39, Redwood City

02115

Takeda Site 45, Boston

K2A 3Z3

Takeda Site 21, Ottawa

M5S 3A3

Takeda Site 11, Toronto

H4J 1C5

Takeda Site 50, Montreal

OO133

Takeda Site 32, Rome

830-0011

Takeda Site 16, Kurume-shi

802-0084

Takeda Site 13, Kitakyushu-shi

812-0025

Takeda Site 14, Fukuoka

222-0033

Takeda Site 9, Kohoku

861-0954

Takeda Site 7, Kumamoto

854-0081

Takeda Site 17, Isahaya-shi

901-2132

Takeda Site 15, Urasoe-Shi

532-0003

Takeda Site 12, Yodogawa

112-0012

Takeda Site 8, Bunkyo-ku

187-8551

Takeda Site 19, Kodaira-shi

151-0053

Takeda Site 20, Shibuya-ku

Unknown

Takeda Site 28, Zwolle

O8036

Takeda Site 36, Barcelona

CH-6900

Takeda Site 51, Lugano

CB2 OAY

Takeda Site 46, Cambridge

SE1 9RT

Takeda Site 52, London

W1G 9ST

Takeda Site 53, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT06470828 - A Study of TAK-861 for the Treatment of Narcolepsy Type 1 | Biotech Hunter | Biotech Hunter